Stocks
Trevi Therapeutics, Inc.TRVI
NASDAQHealthcareBiotechnology$12.61
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for chronic cough and pruritus, with its lead candidate, nalbuphine ER, in late-stage trials for chronic cough associated with idiopathic pulmonary fibrosis. Investors track the stock for its pipeline catalysts and the potential market for treatments in these underserved neurological and respiratory indications.
52W Range: $9.82-$20.22
Congressional Interest in Trevi Therapeutics, Inc. (TRVI)
No congressional trades have been disclosed for Trevi Therapeutics, Inc. (TRVI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TRVI?
No congressional trades found for this stock.